Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy

Summary

This multicenter phase II trial will evaluate palbociclib (PD-0332991) in patients with metastatic urothelial carcinoma (UC) with cyclin-dependent kinase inhibitor 2A (CDKN2A) (also referred to as p16) loss and positive Retinoblastoma (Rb) expression after failure of first-line chemotherapy.

Timeline

Start

2015-03-17

Primary completion

2016-12-02

Completion

2017-09-28

Outcome

Outcome not reported

Stopped: “Data from first 12 subjects-primary endpoint not met. Data analysis underway.”

Drugs

Indications